Meeting
2023 ASCO Annual Meeting
Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.
Authors
Tariq Arshad
Qualigen Therapeutics, San Ramon, CA
Tariq Arshad , Howard Donninger , Becca von Baby , Rachel Ferrill , Joe Burlison , John Trent , Geoffrey J. Clark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4155)
DOI
10.1200/JCO.2023.41.16_suppl.4155
Abstract #
4155
Poster Bd #
476
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203).
First Author: Ramaswamy Govindan
Poster
2023 ASCO Annual Meeting
SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.
First Author: Biagio Ricciuti
Poster
2023 ASCO Annual Meeting
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
First Author: Joshua E. Reuss
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer.
First Author: Saurav Daniel Haldar